- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00434850
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes (CIT-03)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Type 1 diabetes, also known as insulin-dependent diabetes, is a chronic disease in which the pancreas produces insufficient insulin to properly regulate blood sugar levels. Hypoglycemia, low blood sugar, and hyperglycemia, high blood sugar, can lead to significant complications in people with type 1 diabetes. Intensive insulin therapy has been shown to reduce the risk of chronic complications in people who achieve near normalization of glycemia. However, this therapy is labor intensive, difficult to implement, and associated with an increased frequency of severe hypoglycemia. Transplantation of islets from a healthy pancreas has been successful in restoring normal blood sugar levels and has led to initial insulin independence in people with type 1 diabetes. Rejection of these islets by the recipient's immune system, however, makes the treatment ineffective within a couple of years. Immunosuppressant drugs may be an effective way to maintain islet function post-transplant. The purpose of this study is to assess the safety and efficacy of an immunosuppressive regimen that includes DSG on post-transplant islet function in people with type 1 diabetes who have not responded to intensive insulin therapy. The study will also seek to improve the understanding of determinants of success and failure of islet transplants for type 1 diabetes.
Following screening procedures and 2 days prior to islet transplant, participants will be randomly assigned to either this Phase 2 trial or a multicenter Phase 3 trial. Participants in this study will receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
Transplantations will involve an inpatient hospital stay and infusion of islets into a branch of the portal vein. Participants who do not achieve or maintain insulin independence by Day 75 post-transplant will be considered for a second islet transplant. Participants who remain dependent on insulin for longer than 1 month after the second transplant and who show partial graft function will be considered for a third transplant. Daclizumab or basiliximab will be used in place of ATG for the second and third transplants, if they are necessary. Participants who do not meet the criteria for a subsequent transplant and do not have a functioning graft will enter a reduced follow-up period.
There will be up to 21 study visits following each transplant. A physical exam, review of adverse events, blood collection, urine tests, and measures of immunosuppression levels will occur at most visits. An abdominal ultrasound and glomerular filtration rate testing will occur at some study visits. Participants will also self-test their glucose levels at least five times per day throughout the study. A 12-month follow-up period will take place after the participant's last transplant.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
San Francisco, California, Estados Unidos, 94143
- University of Californinia, San Francisco
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Mentally stable and able to comply with study procedures
- Clinical history compatible with type 1 diabetes, with onset of disease at less than 40 years of age; insulin dependence for at least 5 years at study entry; AND sum of age and insulin-dependent diabetes duration of at least 28
- Absent stimulated C-peptide (less than 0.3 ng/ml) 60 and 90 minutes post mixed-meal tolerance test
Involvement of intensive diabetes management, defined as:
- Self monitoring of glucose values no less than a mean of three times each day, averaged over each week
- Administration of three or more insulin injections each day or insulin pump therapy
- Under the direction of an endocrinologist, diabetologist, or diabetes specialist, with at least three clinical evaluations during the past 12 months prior to study enrollment
- At least one episode of severe hypoglycemia, defined as an event with one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, in which the participant was unable to treat him/herself and which was associated with either a blood glucose level less than 54 mg/dl or prompt recovery after an oral carbohydrate, intravenous glucose, or glucagon administration in the 12 months prior to study enrollment.
- Reduced awareness of hypoglycemia. More information about this criterion, including the specific definition of hypoglycemia unawareness, is in the protocol.
Exclusion Criteria:
- Body mass index (BMI) greater than 30 kg/m2 or weight less than or equal to 50 kg
- Insulin requirement of more than 1.0 IU/kg/day or less than 15 U/day
- HbA1c greater than 10%
- Untreated proliferative diabetic retinopathy
- Systolic blood pressure higher than 160 mmHg or diastolic blood pressure higher than 100 mmHg
- Measured glomerular filtration rate using iohexol of less than 80 ml/min/1.73m2. More information about this criterion is in the protocol.
- Presence or history of macroalbuminuria (greater than 300 mg/g creatinine)
- Presence or history of panel-reactive anti-HLA antibody levels greater than background by flow cytometry. More information about this criterion is in the protocol.
- Pregnant, breastfeeding, or unwilling to use effective contraception throughout the study and for 4 months after study completion
- Active infection, including hepatitis B virus, hepatitis C virus, HIV, or tuberculosis. More information about this criterion is in the protocol.
- Negative for Epstein-Barr virus by IgG determination
- Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection in the past year
- History of malignancy except for completely resected squamous or basal cell carcinoma of the skin
- Known active alcohol or substance abuse
- Baseline Hgb below the lower limits of normal, lymphopenia, neutropenia, or thrombocytopenia
- History of Factor V deficiency
- Any coagulopathy or medical condition requiring long-term anticoagulant therapy after transplantation or individuals with an INR greater than 1.5
Severe coexisting cardiac disease, characterized by any one of the following conditions:
- Heart attack within the last 6 months
- Evidence of ischemia on functional heart exam within the year prior to study entry
- Left ventricular ejection fraction less than 30%
- Persistent elevation of liver function tests at the time of study entry
- Symptomatic cholecystolithiasis
- Acute or chronic pancreatitis
- Symptomatic peptic ulcer disease
- Severe unremitting diarrhea, vomiting, or other gastrointestinal disorders that could interfere with the ability to absorb oral medications
- Hyperlipidemia despite medical therapy, defined as fasting LDL cholesterol greater than 130 mg/dl (treated or untreated) and/or fasting triglycerides greater than 200 mg/dl
- Currently receiving treatment for a medical condition that requires chronic use of systemic steroids except for the use of less than or equal to 5 mg prednisone daily, or an equivalent dose of hydrocortisone, for physiological replacement only
- Treatment with any anti-diabetic medication other than insulin within 4 weeks prior to study entry
- Use of any study medications within the past 4 weeks
- Received a live attenuated vaccine within the past 2 months
- Any medical condition that, in the opinion of the investigator, might interfere with safe participation in the trial
- Treatment with any immunosuppressive regimen at the time of enrollment.
- A previous islet transplant.
- A previous pancreas transplant, unless the graft failed within the first week due to thrombosis, followed by pancreatectomy and the transplant occurred more than 6 months prior to enrollment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Allogeneic Pancreatic Islet Cells
Participants in this study can receive up to three separate islet transplants.
They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant.
ATG will continue to be given until Day 2 post-transplant.
Participants will continue taking sirolimus for the duration of the study.
On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus.
The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant.
Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant.
Etanercept will also be administered on Days 3, 7, and 10 post-transplant.
Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
|
Terapia inmunosupresora de mantenimiento
Terapia inmunosupresora de mantenimiento
Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Will replace antithymocyte globulin in all islet transplantations after the first one
Blocks TNF-alpha which is toxic to islet cells
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Proportion of Insulin-independent Subjects
Periodo de tiempo: 75 days following the first islet transplant
|
75 days following the first islet transplant
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percent Reduction in Insulin Requirements
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Hemoglobin A1c (HbA1c)
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Mean Amplitude of Glycemic Excursions (MAGE)
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Glycemic Lability Index (LI)
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Ryan Hypoglycemia Severity Score (HYPO)
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Basal (fasting) and 90-minute Glucose and C-peptide Results
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
Derived from Mixed Meal Tolerance Test (MMTT)
|
75 days following the first and subsequent islet transplant
|
Beta-score
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
Assesses beta-cell function after islet transplantation
|
75 days following the first and subsequent islet transplant
|
C-peptide: Glucose Creatinine Ratio
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
Derived from the insulin-modified frequently sampled intravenous glucose tolerance (FSIGT) test
|
75 days following the first and subsequent islet transplant
|
Glucose Variability and Hypoglycemia Duration
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
Derived from the continuous glucose monitoring system (CGMS)
|
75 days following the first and subsequent islet transplant
|
Quality of Life (QOL) Measure
Periodo de tiempo: 75 days following the first and subsequent islet transplant
|
75 days following the first and subsequent islet transplant
|
|
Incidence of Worsening Retinopathy
Periodo de tiempo: 365 days following the first islet transplant
|
365 days following the first islet transplant
|
|
Proportion of Insulin-independent Subjects
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Percent Reduction in Insulin Requirements
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Hemoglobin A1c (HbA1c)
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Mean Amplitude of Glycemic Excursions (MAGE)
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Glycemic Lability Index (LI)
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Clarke Score
Periodo de tiempo: 365 days following the first and final islet transplant
|
A hypoglycemia score
|
365 days following the first and final islet transplant
|
HYPO Score
Periodo de tiempo: 365 days following the first and final islet transplant
|
A hypoglycemia score
|
365 days following the first and final islet transplant
|
Basal (fasting) and 90-minute Glucose and C-peptide
Periodo de tiempo: 365 days following the first and final islet transplant
|
Derived from Mixed Meal Tolerance Test (MMTT)
|
365 days following the first and final islet transplant
|
Beta-score
Periodo de tiempo: 365 days following the first and final islet transplant
|
Assesses beta-cell function after islet transplantation
|
365 days following the first and final islet transplant
|
C-peptide: Glucose Creatinine Ratio
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Quality of life (QOL) Measure
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Proportion of Subjects Receiving a Second Islet Cell Transplant
Periodo de tiempo: 365 days following the first islet transplant
|
365 days following the first islet transplant
|
|
Proportion of Subjects Receiving a Third Islet Cell Transplant
Periodo de tiempo: 365 days following the first and final islet transplant
|
365 days following the first and final islet transplant
|
|
Incidence and Severity of Adverse Events Related to the Islet Cell Transplant Procedure
Periodo de tiempo: 75 days and 365 days following the first and final islet cell infusion
|
75 days and 365 days following the first and final islet cell infusion
|
|
Incidence and Severity of Adverse Events Related to the Immunosuppression Therapy
Periodo de tiempo: 75 days and 365 days following the first and final islet transplant
|
75 days and 365 days following the first and final islet transplant
|
|
Incidence of a Change in the Immunosuppression Drug Regimen
Periodo de tiempo: 75 days and 365 days following the first and final islet cell transplant
|
75 days and 365 days following the first and final islet cell transplant
|
|
Incidence of Immune Sensitization
Periodo de tiempo: 75 days and 365 days following the first and final islet transplant
|
Defined by detecting anti-HLA antibodies not present prior to transplantation
|
75 days and 365 days following the first and final islet transplant
|
Acute Insulin Response to Glucose, Insulin Sensitivity, and Disposition Index (DI)
Periodo de tiempo: 365 day following the first and final islet transplant
|
Derived from the insulin-modified frequently sampled intravenous glucose tolerance (FSIGT) test
|
365 day following the first and final islet transplant
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Bernhard Hering, MD, University of Minnesota
- Investigador principal: Andrew Posselt, MD, PhD, University of California, San Francisco
- Investigador principal: Xunrong Luo, MD, PhD, Northwestern University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos del metabolismo de la glucosa
- Enfermedades metabólicas
- Enfermedades del sistema inmunológico
- Enfermedades autoinmunes
- Enfermedades del sistema endocrino
- Diabetes mellitus
- Diabetes Mellitus, Tipo 1
- Agentes hipoglucemiantes
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes del sistema nervioso periférico
- Inhibidores de enzimas
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes Gastrointestinales
- Agentes Protectores
- Agentes antibacterianos
- Antibióticos, Antineoplásicos
- Agentes antifúngicos
- Agentes de protección contra la radiación
- Inhibidores de calcineurina
- Etanercept
- Tacrolimus
- Sirolimus
- Basiliximab
- Suero Antilinfocito
- Daclizumab
- Gusperimo
Otros números de identificación del estudio
- DAIT CIT-03
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes Mellitus, Tipo 1
-
University of California, San FranciscoJuvenile Diabetes Research FoundationTerminadoDiabetes mellitus tipo 1 | Diabetes Mellitus, Tipo I | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | IDDMEstados Unidos, Australia
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.TerminadoDiabetes Mellitus, Tipo 1 | Diabetes tipo 1 | Diabetes tipo 1 | Diabetes mellitus tipo 1 | Diabetes autoinmune | Diabetes Mellitus, Insulino-Dependiente | Diabetes de inicio juvenil | Diabetes Autoinmune | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | Diabetes Mellitus... y otras condicionesEstados Unidos
-
Capillary Biomedical, Inc.TerminadoDiabetes Mellitus, Tipo 1 | Diabetes tipo 1 | Diabetes mellitus tipo 1 | Diabetes Mellitus, Insulino-Dependiente, 1Australia
-
Spiden AGDCB Research AGReclutamientoDiabetes mellitus tipo 1 | Diabetes mellitus tipo 1 con hipoglucemia | Diabetes mellitus tipo 1 con hiperglucemiaSuiza
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...DesconocidoDiabetes mellitus tipo 1 con hiperglucemia | Diabetes mellitus tipo 1 con hipoglucemiaPolonia
-
Capillary Biomedical, Inc.TerminadoDiabetes tipo 1 | Diabetes mellitus tipo 1 | Diabetes Mellitus, Tipo I | Diabetes Mellitus, Insulino-Dependiente, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminadoDiabetes mellitus tipo 1 | DM1 | DT1 | Diabetes mellitus tipo 1 de nueva apariciónEstados Unidos, Australia
-
Shanghai Changzheng HospitalReclutamientoDiabetes mellitus frágil tipo 1Porcelana
-
SanofiTerminadoDiabetes Mellitus Tipo 1-Diabetes Mellitus Tipo 2Hungría, Federación Rusa, Alemania, Polonia, Japón, Estados Unidos, Finlandia
-
Hoffmann-La RocheRoche DiagnosticsTerminadoDiabetes Mellitus Tipo 2, Diabetes Mellitus Tipo 1Alemania
Ensayos clínicos sobre Sirolimus
-
Aadi Bioscience, Inc.Aprobado para la comercializaciónTSC1 | TSC2 | PEComa Maligno | Aberración de la vía mTOR
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)TerminadoLinfangioleiomiomatosisEstados Unidos
-
Johns Hopkins UniversityMacuSight, Inc.TerminadoPanuveítis | Uveítis | Uveítis posterior | Uveítis IntermediaEstados Unidos
-
Stefan Schieke MDRetiradoLinfoma cutáneo de células T (LCCT)Estados Unidos
-
Aadi Bioscience, Inc.TerminadoGlioma recurrente de alto grado y glioblastoma recién diagnosticadoEstados Unidos
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... y otros colaboradoresDesconocidoEnfermedad coronariaPorcelana
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyTerminadoEsclerosis tuberosa | Neurofibromatosis | Neurofibroma | AngiofibromaEstados Unidos
-
Cordis CorporationTerminadoEnfermedad de la arteria coronariaBrasil
-
Aucta Pharmaceuticals, IncTerminadoEsclerosis tuberosa | Angiofibroma de caraEstados Unidos, Porcelana
-
Shanghai Jiao Tong University School of MedicineDesconocidoEnfermedad de la arteria coronariaPorcelana